Lupin has collaborated with Alkem subsidiary Enzene Biosciences to launch the first ever cetuximab biosimilar in India. 

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.

An Indian court has directed a local firm to pay a specified sum to Pfizer for contempt of court in a case pertaining to its patent on palbociclib, failing which its senior executive could face a two-week prison term.